China healthcare : a growing force
Contenido multimedia no disponible por derechos de autor o por acceso restringido. Contacte con la institución para más información.
| Tag | 1 | 2 | Value |
|---|---|---|---|
| LDR | 00000cam a22000004b 4500 | ||
| 001 | MAP20210020810 | ||
| 003 | MAP | ||
| 005 | 20220912143242.0 | ||
| 008 | 210625e20210528usa|||| ||| ||eng d | ||
| 040 | $aMAP$bspa$dMAP | ||
| 084 | $a931.2 | ||
| 100 | 1 | $0MAPA20210009129$aLeverenz, Justin | |
| 245 | 0 | 0 | $aChina healthcare$b: a growing force$cJustin Leverenz |
| 260 | $aAtlanta$bInvesco$c2021 | ||
| 520 | $aOver the past few years, the Chinese health care system has undergone significant reform. Initiatives to stimulate innovation, especially around drug research and development (R&D), have been the most impactful, in our view. The result is a booming drug R&D ecosystem including quality biotechs and their R&D outsourcing partner companies | ||
| 650 | 4 | $0MAPA20080539771$aSalud | |
| 650 | 4 | $0MAPA20080564872$aBiotecnología | |
| 650 | 4 | $0MAPA20080554866$aInnovación | |
| 651 | 1 | $0MAPA20080644178$aChina | |
| 710 | 2 | $0MAPA20210000980$aInvesco | |
| 773 | 0 | $iInvesco$d28 May 2021 |